Robert Arthur, MD
Rheumatology · Oklahoma City, OKNPI 1275531519
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Gilead at 36.6% of the total. Reporting peaked in 2020 at $6,432 and has fallen 97.8% since, to $140 in 2025.
Across 282 payments — averaging $58.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Johnson & Johnson$5K
- Amgen$1K
- AstraZeneca$851
- Janssen Scientific Affairs, LLC$628
- GSK$475
- plus $3K from 13 others
What the payments were for
- Consulting fees$8,19050%
- Travel & lodging$1,58410%
- Food & beverage$6,44739%
- Education$1971%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 9 | $6,016 |
| Johnson & Johnson | 46 | $4,796 |
| Amgen(2 entities) | 43 | $1,100 |
| AstraZeneca | 14 | $851 |
| Janssen Scientific Affairs, LLC | 8 | $628 |
| GSK | 18 | $475 |
| AbbVie | 20 | $405 |
| UCB, Inc. | 20 | $384 |
| Lilly USA, LLC | 16 | $372 |
| E.r. Squibb & Sons, L.L.C. | 20 | $238 |
| Pfizer | 39 | $217 |
| Novartis | 12 | $195 |
| Genentech USA, Inc. | 9 | $165 |
| Sanofi | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $123 |
| Bristol Myers Squibb | 2 | $116 |
| Aurinia Pharma U.S., Inc. | 1 | $104 |
| Boehringer Ingelheim | 2 | $89 |
| Organon | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,418 in reported general payments places this provider in the 80th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Leflunomide | 61 | $6,398 |
| Hydroxychloroquine Sulfate | 75 | $3,232 |
| MethotrexateMethotrexate Sodium | 85 | $2,723 |
| Pilocarpine Hcl | 26 | $2,386 |
| Sulfasalazine | 51 | $1,749 |
| Gabapentin | 38 | $726 |
| Allopurinol | 37 | $499 |
| Prednisone | 23 | $247 |
| Tramadol Hcl | 23 | $117 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Oklahoma City
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Mohammad KhanOklahoma City$94K
- Cristina ArriensOklahoma City$82K
- John GoetzingerOklahoma City$18K
- Muhammad GillanOklahoma City$16K
- William SchnitzOklahoma City$15K
- Judith JamesOklahoma City$15K
- Amanda TitusOklahoma City$13K
- Michael PickrellOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.